Can Persistent Infections with Hepatitis B Virus, Hepatitis C Virus, Human Immunodeficiency Virus, and Human T Lymphotropic Virus Type 1 Be Eradicated?

HBV HCV HIV-1 HTLV-1 HTLV-2 persistent viruses

Journal

AIDS research and human retroviruses
ISSN: 1931-8405
Titre abrégé: AIDS Res Hum Retroviruses
Pays: United States
ID NLM: 8709376

Informations de publication

Date de publication:
22 Aug 2023
Historique:
pubmed: 6 7 2023
medline: 6 7 2023
entrez: 6 7 2023
Statut: aheadofprint

Résumé

Persistent viruses are hard to be eradicated, even using effective medications, and can persist for a long time in humans, sometimes regardless of treatment. Hepatitis B virus, hepatitis C virus, human immunodeficiency virus, and human T cell lymphotropic virus infections, the most common in our era, are still a challenge despite the increased knowledge about their biology. Most of them are highly pathogenic, some causing acute disease or, more often, leading to chronic persistent infections, and some of the occult, carrying a high risk of morbidity and mortality. However, if such infections were discovered early, they might be eradicated in the near future with effective medications and/or vaccines. This perspective review points out some specific characteristics of the most important chronic persistent viruses. It seems that in the next few years, these persistent viruses may have control by vaccination, epidemiological strategies, and/or treatment.

Identifiants

pubmed: 37409405
doi: 10.1089/AID.2022.0116
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Sandy Vieira Teixeira (S)

Laboratory of Medical Investigation in Dermatology and Immunodeficiencies (LIM-56), Department of Dermatology, Hospital das Clinicas HCFMUSP, Faculty of Medicine, University of São Paulo, São Paulo, São Paulo, Brazil.

Gabriela Prates (G)

Laboratory of Medical Investigation in Dermatology and Immunodeficiencies (LIM-56), Department of Dermatology, Hospital das Clinicas HCFMUSP, Faculty of Medicine, University of São Paulo, São Paulo, São Paulo, Brazil.

Luiz Augusto Marcondes Fonseca (LA)

Laboratory of Medical Investigation in Dermatology and Immunodeficiencies (LIM-56), Department of Dermatology, Hospital das Clinicas HCFMUSP, Faculty of Medicine, University of São Paulo, São Paulo, São Paulo, Brazil.

Jorge Casseb (J)

Laboratory of Medical Investigation in Dermatology and Immunodeficiencies (LIM-56), Department of Dermatology, Hospital das Clinicas HCFMUSP, Faculty of Medicine, University of São Paulo, São Paulo, São Paulo, Brazil.

Classifications MeSH